Pfizer begins Phase 2/3 study for COVID-19 oral antiviral in exposed adults
September 27, 2021 at 10:02 AM EDT
Pfizer initiated a Phase 2/3 study of an investigational oral antiviral with a low dose of ritonavir to prevent COVID-19 illness, the company announced Monday.
